

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2026 Company Presentations

All items marked with an \* are mandatory to complete.

The maximum number of words for this abstract is 400.

Please be sure to complete the following:

Company name: Aevum Labs \* Website <https://www.aevumlabs.bio>\*

CEO name Roy Friedman\*

Select a CATEGORY: Biotech/Pharma **or** Bio Convergence\*

(Delete categories you are not selecting)

Select one SESSION per abstract from the list below \*

(Delete sessions you are not selecting)

1. The Future of Aging: Where Longevity Meets Innovation

You may delete the section instructions, leaving only the bolded bullet title.  
Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational:**

Aevum Labs is a Weizmann Institute spin-out founded to radically extend humanity's healthspan and lifespan. We simulate senescence - a key biological process in aging, 30+ age-related diseases, and cancer. This unlocks a robust foundry engine, while enabling rapid evaluation of therapeutic efficacy across the drug development lifecycle. We're currently engaging with big pharma, researchers, healthcare, and clinical organizations.

- **Core Technology: What is the technology, its uniqueness, and its value proposition?**

We combine a proprietary AI architecture redefining how biology is modeled at scale - it connects siloed data types with zero information loss while drastically reducing costs and time - with the world's first method for quantifying tissue-specific senescence from blood, developed at the Weizmann Institute. We use these to create a world model of aging that powers new set of products.

- **Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.**

We validated scientifically three commercialization pathways - foundry engine for senotherapeutics, rapid evaluation of therapies, and a new kind of computational platform. We have already developed capabilities enabling the evaluation of therapies and the computational platform.

These days, we are engaging with big pharma, researchers, healthcare & clinical organizations

We also secured strategic partnership to acquire a unique dataset.

- **Business Strategy:**

We're creating a foundry engine for assets that revert aging, and plan to enroll it with large-scale partnership with selected pharma.

Our technology is already powering a new class of evaluation platform delivering fast, molecular-level readouts of impact across the drug development lifecycle, avoiding months-long waits. It also powers a computational platform outperforming current methods in accuracy, time, and costs.

- **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans**

We plan to further develop our models, building an ever-learning and improving AI infrastructure. We are aiming to expand our models capabilities to additional organ systems and indications. We are expected later this year to establish our lab and start preclinical studies for our technology as well.